Entera Bio Provides Guidance from FDA Type D Meeting Related to EB613 Pivotal Program
April 03, 2023 07:00 ET
|
Entera Bio Ltd.
JERUSALEM, April 03, 2023 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) (“Entera” or the “Company”) a leader in the development of orally delivered peptides and therapeutic proteins, today...
Entera Bio Provides 2022 Corporate Milestones and Financial Results for the Year Ended December 31, 2022
March 31, 2023 16:00 ET
|
Entera Bio Ltd.
JERUSALEM, March 31, 2023 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides and therapeutic proteins, today...
Entera Bio Regains Compliance with Nasdaq Listing Requirements
March 23, 2023 09:27 ET
|
Entera Bio Ltd.
JERUSALEM, March 23, 2023 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides and therapeutic proteins, announced...
Entera Bio Announces FDA’s Acceptance of a Type D Meeting Review to Affirm Design of the Pivotal, Phase 3 Protocol for EB613 PTH Mini Tablets, as the First Oral Osteoanabolic Treatment of Post-Menopausal Osteoporosis
February 15, 2023 10:00 ET
|
Entera Bio Ltd.
Type D meeting protocol submission builds on concurrence reached with FDA following successful Type C meeting and supports potential Phase 3 initiation in H2 2023 JERUSALEM, Feb. 15, 2023 (GLOBE...
Entera Bio to Participate in the SVB Securities Global Biopharma Conference
February 13, 2023 09:00 ET
|
Entera Bio Ltd.
JERUSALEM, Feb. 13, 2023 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a late-clinical stage, leader in the development of orally delivered peptides and therapeutic...
Entera Bio Provides Corporate Updates and Financial Results for the Third Quarter of 2022
November 10, 2022 16:15 ET
|
Entera Bio Ltd.
JERUSALEM, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides and therapeutic proteins, today...
Entera Bio Announces FDA Agreement for a Single Phase 3 Clinical Trial to Support an NDA for EB613 for the Treatment of Osteoporosis
October 06, 2022 07:00 ET
|
Entera Bio Ltd.
JERUSALEM, Oct. 06, 2022 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides and therapeutic proteins, announced...
Entera Bio Hosting Key Opinion Leader Webinar on the Treatment Landscape for Osteoporosis and EB613’s Potential Impact on Wednesday, September 28th @ 10am ET
September 21, 2022 08:30 ET
|
Entera Bio Ltd.
JERUSALEM, Sept. 21, 2022 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”), a leader in the development of orally delivered peptides and therapeutic proteins, today...
Entera Bio to Present at H.C. Wainwright 24th Annual Global Investment Conference
September 12, 2022 16:30 ET
|
Entera Bio Ltd.
JERUSALEM, Sept. 12, 2022 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides and therapeutic proteins, today...
Entera Bio Presents Dose Proportional Absorption and Correlation to BMD Clinical Response Data from its Phase 2 Study of EB613 in Post-Menopausal Osteoporosis Patients at the ASBMR 2022 Annual Meeting
September 12, 2022 06:30 ET
|
Entera Bio Ltd.
JERUSALEM, Sept. 12, 2022 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides and therapeutic proteins, today...